Monopar Therapeutics Reports Officer/Director Changes & Compensatory Info

Ticker: MNPR · Form: 8-K · Filed: 2025-03-03T00:00:00.000Z

Sentiment: neutral

Topics: management-change, compensation, corporate-governance

Related Tickers: MNPR

TL;DR

Monopar's leadership team is seeing changes, with new officers potentially appointed and executive pay structures updated.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on March 3, 2025, reporting events as of February 27, 2025. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.

Why It Matters

This filing indicates potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in key personnel and executive compensation can signal internal shifts that may affect future performance or strategy.

Key Players & Entities

FAQ

Who has departed from Monopar Therapeutics' board or officer positions?

The filing indicates the 'Departure of Directors or Certain Officers' as a reported item, but specific names are not detailed in the provided text.

Were any new directors or officers elected or appointed?

Yes, the filing explicitly lists 'Election of Directors' and 'Appointment of Certain Officers' as items being reported.

What is the nature of the compensatory arrangements being disclosed?

The filing mentions 'Compensatory Arrangements of Certain Officers,' suggesting details about executive pay are being provided.

What is the exact date of the events reported in this 8-K?

The earliest event reported is dated February 27, 2025.

What other information is included in this filing besides personnel changes?

The filing also includes 'Financial Statements and Exhibits'.

From the Filing

0001437749-25-005951.txt : 20250303 0001437749-25-005951.hdr.sgml : 20250303 20250303171538 ACCESSION NUMBER: 0001437749-25-005951 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250227 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250303 DATE AS OF CHANGE: 20250303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 25699551 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20250228_8k.htm FORM 8-K mnpr20250228_8k.htm false 0001645469 0001645469 2025-02-27 2025-02-27     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 27, 2025   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On February 28, 2025, Karthik Radhakrishnan’s employment with Monopar Therapeutics Inc. (the “Company” or “Monopar”) terminated. As of such date, Mr. Radhakrishan will no longer serve as the Company’s Chief Financial Officer, principal financial officer, or principal accounting office

View on Read The Filing